· Affordable treatment for Overactive Bladder (OAB)–a widely prevalent problem among men and women in India
· First-line therapy recommended by various international treatment guidelines
Hyderabad, 15th March, 2023 (GNI): MSN Labs, a research-based and fully-integrated global pharmaceutical company based out of Hyderabad, announced the launch of Fesobig, world’s first bioequivalent generic version of Fesoterodine Fumarate.Fesobigis recommended as the safest, novel first line pharmacotherapy option by various international treatment guidelines for the treatment of overactive bladder (OAB) and Uninary Incontinence (UI).
“The launch of Fesobig (Fesoterodine) tablets is in line with our ongoing commitment toresearch inbringing affordable medications across critical therapies for alleviatingthe suffering of the Indian patients.” Dr. M.S.N. Reddy, Chairman & Managing Director, MSN Group commented.
Speaking on occasion, Mr. Bharat Reddy, Executive Director, MSN Group, said, “Besides helping recover from overactive bladder (OAB), we are certain that Fesobig will endow patients with a much confident way of life by eliminating the social and psychological discomfort associated with the condition. We have ensured that drug is priced affordably so that it can benefit a vast majority of patients.”
The guest speakers Dr K Lalitha, consultant urologist spoke on the prevalence of OAB in India. According to the studies,1 in 3 womenabove the age of 50 suffer from urinary incontinence impacting their quality of life.
Dr Anuradha Koduri, HOD – Gynecology, KIMS Hospital, spoke on the social stigma associated with the condition andstated that a majority of patients shy away from treatment due to the lack of awareness and accept it as a part of ageing process.This, in the long run,leads to various medical complications.
Dr A V Ravikumar, consultant urologist further elucidatedon the various medical avenues including behavioral therapy, drugs and surgical options available in treating OAB, stated in a press release.
About Overactive Bladder disorder (OAB): Overactive Bladder disorder (OAB) is involuntary leakage of urine resulting from pelvic floor dysfunction and is strongly associated with the female gender. The prevalence of UI in India is also relatively high, ranging from 10% in rural areas to 34% in urban areas. Although UI is not a threat to life, it causes discomfort, shame, and loss of self-confidence.
Patients suffering from overactive bladder problems suffer from urgency to empty the bladder with increased daytime frequency. Symptoms can affect psychological, social, occupational, domestic and sexual aspects of life. Its prevalence increases with age, and due to a lack of awareness, only a small percentage are diagnosed and receive the treatment.
About MSN Group is one of the fastest-growing, research-based and fully integrated pharmaceutical companies based out of Hyderabad, India. It was founded in the year 2003 with a mission to make high-quality medicines affordable and accessible to the world. The organization presently has 21 state-of-the-art manufacturing facilities (fifteen API and six finished dosage facilities) in India and USA. The Group has an integrated R&D center which facilitates both API and formulation research under one roof. With its core focus on speed and consistency in delivery, MSN is credited with 900+ national and international patents filed, 150+ ANDAs, and emerged as World no. 1 in active US DMF filings. The company, with a product portfolio of 450+ APIs and 300+ formulations spanning over 35 major therapies, and has won the trust of more than 40 million patients in 80+ countries across the world. For more details pls contact on: balaji.ramgiri@msnlabs.com, ends GNI SG
Be the first to comment on "MSN Group launches India’s First and the most beneficial urinary incontinence drug"